Cabaletta Bio, Inc. (CABA)

13,68 +0,36 (+2,70%) Ab 02:59PM EDT. Markt geöffnet.

Cabaletta Bio, Inc.

2929 Arch Street
Suite 600
Philadelphia, PA 19104
United States
267 759 3100
https://www.cabalettabio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 101

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Steven A. Nichtberger M.D.	Co-Founder, Chairman, CEO & President	970,6k	N/A	1961
Dr. Gwendolyn K. Binder Ph.D.	President of Science & Technology	692,99k	N/A	1975
Dr. David J. Chang FACR, M.D., M.P.H.	Chief Medical Officer	676,74k	N/A	1964
Dr. Michael C. Milone M.D., Ph.D.	Co-Founder & Co-Chair of Scientific Advisory Board	N/A	N/A	N/A
Dr. Aimee Payne M.D., Ph.D.	Co-Founder & Co-Chair of Scientific Advisory Board	N/A	N/A	N/A
Mr. Anup Marda M.B.A.	Chief Financial Officer	548,2k	N/A	1978
Dr. Samik Basu M.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Michael Gerard J.D.	General Counsel & Secretary	N/A	N/A	1980
Ms. Heather Harte-Hall M.Sc.	Chief Compliance Officer	N/A	N/A	N/A
Ms. Martha O'Connor	Chief Human Resources Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Corporate Governance

Cabaletta Bio, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 10. Die grundlegenden Scores sind Audit: 6, Vorstand: 9, Shareholderrechte: 10, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.